Registration: 2023.03.28 09:43:11 Modification: 2023.03.28 09:43:14
Dailybet Manager
Bionote Co., Ltd., a company specializing in animal diagnosis, vaccine, and bio contents, announced on the 27th that it would renew the package design of ‘CaniFlu-max’, a canine influenza vaccine.
Bionote’s Caniflu-Max is Korea’s first canine influenza vaccine developed and launched in 2009.
As it has been used in veterinary hospitals for over 10 years, the incidence of side effects compared to cumulative sales following launch was confirmed to be less than 1/250,000. Bionote emphasized, “It is a vaccine whose safety has been verified enough to be classified as ‘very rare’ even by international safety standards.”
Caniflu-Max is the only canine influenza vaccine in Korea that has been approved for use in 3-4 week old puppies.
Bionote explained, “It is manufactured in a cell culture method rather than fertilized egg culture, so there is a low possibility of causing allergies.
Canine influenza is a highly contagious disease that can lead to fatal symptoms such as pneumonia accompanied by high fever in dogs with low immunity. Prevention is best through early vaccination.
Bionote said, “As a result of comparing the HA gene homology of Caniflu-Max’s vaccine strain with the canine influenza virus (H3N2) isolated recently in Korea, a 97.7% concordance rate was confirmed.” There is,” he said.
Caniflu-Max also signed a vaccine patent license contract with a global pharmaceutical company abroad.
Bionote emphasized, “We are grateful to the many clinical veterinarians who have loved Caniflu-Max so far,” and “we will continue to contribute to the healthy coexistence of humans and animals with better diagnostic products and vaccines.”
Caniflu-Max can be purchased through Green Cross Veterinary Medicine (Seoul), Bioline (all regions except Seoul), and SMP Animal Pharm (Gyeonggi, Incheon).
share
